RLF Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Core Viewpoint - Rosen Law Firm is reminding purchasers of Agenus Inc. securities about a class action lawsuit with a lead plaintiff deadline of November 5, 2024, for those who bought shares between January 23, 2023, and July 17, 2024 [1] Group 1: Class Action Details - Investors who purchased Agenus securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3] - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 [3] Group 3: Case Allegations - The lawsuit alleges that Agenus made false and misleading statements regarding the effectiveness of its combination therapy involving botensilimab and balstilimab, overstating their clinical results and commercial prospects [4] - As a result of these misleading statements, investors suffered damages when the true details became public [4]